Sign up
Pharma Capital

ReNeuron pleased to secure podium presentation for stroke data at US conference

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) tells Proactive positive long-term data on their CTX cell therapy for stroke has been presented at the American Heart Association International Stroke Conference in Los Angeles.

Professor Keith Muir, of the Queen Elizabeth University Hospital, Glasgow and Principal Investigator for ReNeuron’s PISCES II study, told the audience that upper limb functional recovery was “durable and maintained” out to 12 months post-treatment.

 

View full RENE profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.